CD109 (Cluster of Differentiation 109) is a human gene.[1]
CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets (Lin et al., 2002). In addition, the platelet-specific Gov antigen system, implicated in refractoriness to platelet transfusion, neonatal alloimmune thrombocytopenia, and posttransfusion purpura, is carried by CD109 (Kelton et al., 1990; Lin et al., 2002).[supplied by OMIM][1]
Lucas GF, Metcalfe P (2000). "Platelet and granulocyte glycoprotein polymorphisms". Transfusion medicine (Oxford, England). 10 (3): 157–74. doi:10.1046/j.1365-3148.2000.00250.x. PMID10972910.
Sutherland DR, Yeo E, Ryan A, et al. (1991). "Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets". Blood. 77 (1): 84–93. PMID1984805.
Kelton JG, Smith JW, Horsewood P, et al. (1990). "Gova/b alloantigen system on human platelets". Blood. 75 (11): 2172–6. PMID2346781.
Lin M, Sutherland DR, Horsfall W, et al. (2002). "Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins". Blood. 99 (5): 1683–91. doi:10.1182/blood.V99.5.1683. PMID11861284.
Schuh AC, Watkins NA, Nguyen Q, et al. (2002). "A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens". Blood. 99 (5): 1692–8. doi:10.1182/blood.V99.5.1692. PMID11861285.
Giesert C, Marxer A, Sutherland DR, et al. (2003). "Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34- hematopoietic and mesenchymal stem cell subsets". Ann. N. Y. Acad. Sci. 996: 227–30. doi:10.1111/j.1749-6632.2003.tb03250.x. PMID12799300.
Mungall AJ, Palmer SA, Sims SK, et al. (2003). "The DNA sequence and analysis of human chromosome 6". Nature. 425 (6960): 805–11. doi:10.1038/nature02055. PMID14574404.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID14702039.
Solomon KR, Sharma P, Chan M, et al. (2004). "CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family". Gene. 327 (2): 171–83. doi:10.1016/j.gene.2003.11.025. PMID14980714.
Zhang JM, Hashimoto M, Kawai K, et al. (2005). "CD109 expression in squamous cell carcinoma of the uterine cervix". Pathol. Int. 55 (4): 165–9. doi:10.1111/j.1440-1827.2005.01807.x. PMID15826242.
Lewandrowski U, Moebius J, Walter U, Sickmann A (2006). "Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach". Mol. Cell. Proteomics. 5 (2): 226–33. doi:10.1074/mcp.M500324-MCP200. PMID16263699.
Finnson KW, Tam BY, Liu K, et al. (2006). "Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes". FASEB J. 20 (9): 1525–7. doi:10.1096/fj.05-5229fje. PMID16754747.
Sjöblom T, Jones S, Wood LD, et al. (2006). "The consensus coding sequences of human breast and colorectal cancers". Science. 314 (5797): 268–74. doi:10.1126/science.1133427. PMID16959974.
Hasegawa M, Hagiwara S, Sato T, et al. (2007). "CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells". Pathol. Int. 57 (5): 245–50. doi:10.1111/j.1440-1827.2007.02097.x. PMID17493171.